Intramuscular versus intravenous immunoglobulin replacement therapy and measurement of immunoglobulin levels during immunoglobulin replacement therapy

Journal of Allergy and Clinical Immunology: In Practice

Volumn 1, Issue 6, 2013, Pages 705-706

  Lieberman, Phillip ^a   Berger, Melvin ^b  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b CSL Behring LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

DRUG BIOAVAILABILITY; DRUG EFFICACY; EDITORIAL; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; IMMUNOLOGIC DEFICIENCY SYNDROMES; INTRAMUSCULAR DRUG ADMINISTRATION; PASSIVE IMMUNIZATION; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION;

HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN M; IMMUNOLOGIC DEFICIENCY SYNDROMES; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS;

EID: 84887001246     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2013.08.007     Document Type: Editorial

References (9)

1. Medical Research Council Working Party Hypogammaglobulinemia in the UK. Lancet 1969, 1:163-168.
2. Amman A.J., Ashman R.F., Buckley R.H., Hardie W.R., Krantmann H.J., Nelson J., et al. Use of Intravenous γ-globulin in antibody immunodeficiency: results of a multicenter controlled trial. Clin Immunol Immunopathol 1982, 22:60-67.
3. Buckley R.H. Long term use of intravenous immune globulin in patients with primary immunodeficiency diseases: inadequacy of current dosage practices and approaches to the problem. JClin Immunol 1982, 2(Suppl):15S-21S.
4. Pirofsky B. Intravenous immune globulin therapy in hypogammaglobulinemia. Am J Med 1984, 76:78-82.
5. Berger M., Jolles S., Orange J.S., Sleasman J.W. Bioavailability of IgG administered by the subcutaneous route. JClin Immunol 2013, 33:984-990.
6. Ochs H., Gupta S., Kiessling P., Nicolay U., Berger M. Safety and efficacy of self-administered immunoglobulin in patients with primary immunodeficiency diseases. JClin Immunol 2006, 26:265-273.
7. Wasserman R.L., Irani A.M., Tracy J., Tsoukas C., Stark D., Levy R., et al. Pharmacokinetics and safety of subcutaneous immune globulin (human) 10% caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol 2010, 161:518-526.
8. Wasserman R.L., Melamed I., Nelson R.P., Knutsen A.P., Fasano M.B., Stein M.R., et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet 2011, 50:405-414.
9. Berger M., Rojavin M., Kiessling P., Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol 2011, 139:133-141.